This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Batchelor, W. B. Search for Related Content PubMed PubMed Citation Articles by Batchelor, W. B.

A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial

Wayne B. Batchelor, MD, MHS^*, Kenneth W. Mahaffey, MD, FACC^*, Peter B. Berger, MD, FACC, Ezra Deutsch, MD, Susan Meier, BS, Vic Hasselblad, PhD^*, Edward T. Fry, MD^||, Paul S. Teirstein, MD, FACC^¶, Allan M. Ross, MD, FACC^#, Cynthia A. Binanay, RN^*, James P. Zidar, MD, FACC^*,* the ATLAST Trial Investigators

^* the Duke Clinical Research Institute, Durham, North Carolina, USA
Mayo Clinic, Rochester, Minnesota, USA
New York Presbyterian Hospital, New York, New York, USA
Aventis Pharma, Bridgewater, New Jersey, USA
^|| St. Vincent’s Hospital, Indianapolis, Indiana, USA
^¶ Scripps Clinic, La Jolla, California, USA
^# George Washington University, Washington, D.C., USA

View larger version (14K): [in a new window]   Figure 1 Odds ratios and 95% confidence intervals for the risk of primary and secondary 30-day clinical events with enoxaparin versus placebo. UR = urgent revascularization.